//Your Connection to the Life Sciences Industry
Connect to IBC:LinkedIn iconTwitter iconFacebook iconBlog iconRSS icon
EmailPrint

News

Well Characterized Biologicals boasts impressive lineup
Well Characterized Biologicals boasts impressive lineup
10/15/2009

IBC's 13th Annual Well Characterized Biologicals conference is loaded with the latest new content to help you overcome your protein characterization challenges and develop strategies to implement new technologies in your own laboratories.

  • 17 presentations (half the talks!) feature unpublished new data so you can be sure that the information you will learn has not been heard at other conferences or read in any trade journals.
  • 13 presentations feature case studies that provide lessons learned from industry leading companies and their real experiences, trials and tribulations in protein characterization.
  • 6 presentations will be delivered by FDA speakers who will share their insights and perspectives into the ever-evolving guidelines that regulate your products.

With 6 presentations from the FDA, 6 from Genentech, 4 from Amgen, 3 from Biogen Idec, 3 from Pfizer, 2 from Merck, 2 from MedImmune and others by BMS, Lilly and Genzyme, it's no secret why IBC's Well Characterized Biologicals conference has been such a well respected, must-attend event in the bioprocess industry for over 12 years.

Download the brochure or visit the conference website for more information on this one-of-a-kind event.

New This Year! Well Characterized Biologicals will be immediately followed by IBC's intensive, science and strategy-focused two day conference on De-Risking Next Generation Biologics: Capabilities & Strategies to Develop BioBetters, Biosimilars and Follow-ons. Stay the full week and you will not only maximize your travel dollar, but you will also have the chance to learn how innovator, generic and technology companies companies are reducing risk and capitalizing on new opportunities in biologics drug development across the spectrum of products from BioBetters to Biosimilars and Follow-ons.